source
- Capricor Therapeutics sees stock surge as FDA signals openness to extend review of DMD cell therapyCapricor Therapeutics' CEO Linda Marbán told investors that the FDA is receptive to adding open label extension data to its Biologics License Application for deramiocel, its Duchenne muscular dystr…
- CLINUVEL to cut up to 20% of staff and move headquarters to New YorkCLINUVEL announced a strategic reorganization aimed at focusing resources on the U.S. market. The company will reduce its global workforce by 10% to 20%, affecting up to 21 of its 104 employees.…